177 related articles for article (PubMed ID: 35474239)
1. Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.
Zhao H; Dong Z; Wan D; Cao W; Xing H; Liu Z; Fan J; Wang H; Lu R; Zhang Y; Cheng Q; Jiang Z; He F; Xie X; Guo R
Sci Rep; 2022 Apr; 12(1):6752. PubMed ID: 35474239
[TBL] [Abstract][Full Text] [Related]
2. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
3. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma.
Shimizu H; Saitoh T; Tanaka M; Mori T; Sakura T; Kawai N; Kanda Y; Nakaseko C; Yano S; Fujita H; Fujisawa S; Miyawaki S; Kanamori H; Okamoto S
Leukemia; 2012 Dec; 26(12):2469-73. PubMed ID: 22699453
[TBL] [Abstract][Full Text] [Related]
4. [Clinical outcome of allogeneic hematopoietic stem cell transplantation in the treatment of 9 myeloid leukemia patients with granulocytic sarcoma].
Liang LJ; Zhou J; Zhang YL; Fu YW; Zu YL; Yu FK; Lin QD; Han LJ; Wang Q; Fang BJ; Wei XD; Song YP
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):216-219. PubMed ID: 29518868
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
6. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey.
Lazzarotto D; Candoni A; Filì C; Forghieri F; Pagano L; Busca A; Spinosa G; Zannier ME; Simeone E; Isola M; Borlenghi E; Melillo L; Mosna F; Lessi F; Fanin R
Leuk Res; 2017 Feb; 53():74-81. PubMed ID: 28056398
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
[TBL] [Abstract][Full Text] [Related]
9. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
10. Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.
Frietsch JJ; Hunstig F; Wittke C; Junghanss C; Franiel T; Scholl S; Hochhaus A; Hilgendorf I
Bone Marrow Transplant; 2021 Jan; 56(1):101-109. PubMed ID: 32606455
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of risk factors of relapse after allogeneic hematopoietic stem cell transplantation in patients with t (8;21) acute myeloid leukemia].
Guo WW; Liu X; Pang AM; Zhai WH; Yang DL; Chen X; Ma QL; He Y; Zhang RL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):998-1004. PubMed ID: 35045670
[No Abstract] [Full Text] [Related]
12. Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study.
Yu WJ; Sun YQ; Han TT; Ye PP; Zhang XH; Xu LP; Liu KY; Yan CH; Huang XJ; Wang Y
Ann Hematol; 2021 Mar; 100(3):799-808. PubMed ID: 33416901
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
14. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].
Wu TM; Xue SL; Li Z; Yu JQ; Wang J; Wang BR; Wan CL; Shen XD; Qiu QC; Bao XB; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):646-653. PubMed ID: 34547870
[No Abstract] [Full Text] [Related]
16. Characteristics and transplant outcome of myeloid sarcoma: a single-institute study.
Shan M; Lu Y; Yang M; Wang P; Lu S; Zhang L; Qiu H; Chen S; Xu Y; Zhang X; Wu D
Int J Hematol; 2021 May; 113(5):682-692. PubMed ID: 33511548
[TBL] [Abstract][Full Text] [Related]
17. [Effects of pre-transplant course on prognosis of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia].
Liu XJ; Huang XJ; Xu LP; Liu KY; Zhang XH; Yan CH; Wang Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):182-186. PubMed ID: 30929382
[No Abstract] [Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
19. Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
D'Angelo CR; Hall A; Woo KM; Kim K; Longo W; Hematti P; Callander N; Kenkre VP; Mattison R; Juckett M
Leuk Res; 2020 Sep; 96():106419. PubMed ID: 32683127
[TBL] [Abstract][Full Text] [Related]
20. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]